Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature.

about

Molecular Determinants of Malignant Brain Cancers: From Intracellular Alterations to Invasion Mediated by Extracellular Vesicles.Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications.

P2860

Q47183915-48B9C940-FC9A-4CE7-A9E1-A71B2899216D Q47942947-B23F9639-9962-4289-B412-1F6ED9CF59F5

P2860

Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature.

Item

http://www.wikidata.org/entity/Q39436924

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Clinical outcomes in recurrent ...... An analysis of the literature.

@en

Clinical outcomes in recurrent ...... An analysis of the literature.

@nl

type

Item

label

Clinical outcomes in recurrent ...... An analysis of the literature.

@en

Clinical outcomes in recurrent ...... An analysis of the literature.

@nl

prefLabel

Clinical outcomes in recurrent ...... An analysis of the literature.

@en

Clinical outcomes in recurrent ...... An analysis of the literature.

@nl

P1476

Clinical outcomes in recurrent ...... An analysis of the literature.

@en

P2093

H Ian Robins

http://www.w3.org/2001/XMLSchema#string

Jens Eickhoff

http://www.w3.org/2001/XMLSchema#string

Matthew Tipping

http://www.w3.org/2001/XMLSchema#string

P2860

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma

A randomized trial of bevacizumab for newly diagnosed glioblastoma

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

Bevacizumab and daily temozolomide for recurrent glioblastoma.

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.

Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

Retrospective analysis of bevacizumab in combination with fotemustine in chinese patients with recurrent glioblastoma multiforme.

P304

101-106

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JOCN.2017.06.070

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28711289

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

5581989

http://www.w3.org/2001/XMLSchema#string

Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature.

about

P2860

P2860

Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P932